Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01842646 · ClinicalTrials.gov registry record · Phase 2
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01842646 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 35 participants.
The verdict
NCT01842646, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is being done to see how safe an investigational drug is and test how well it will work to help people with refractory/relapsed myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).
Interventions
- DRUG PF-04449913
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2013-08-29 |
| Est. Completion | 2021-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01842646
The ClinicalTrials.gov registry entry for NCT01842646 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04449913 is the first listed.
NCT01842646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01842646 about?
NCT01842646 is a clinical study titled "Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)". This study is being done to see how safe an investigational drug is and test how well it will work to help people with refractory/relapsed myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).
What is the current status of trial NCT01842646?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2013-08-29. Estimated completion is 2021-06-10.
What interventions are being tested in trial NCT01842646?
The interventions under investigation include: PF-04449913 (DRUG).
Who is sponsoring clinical trial NCT01842646?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.